Testing talimogene laherparepvec for skin bumps in adults with NF1
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a drug called IMLYGIC (talimogene laherparepvec) to see if it is safe and tolerable for treating skin bumps (cutaneous neurofibromas) in adults with NF1. The drug is injected directly into the bumps, and the study will check if it can shrink them or improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with NF1.
- You have at least 8 skin bumps that are between 5 mm and 5 cm in size, are not on irritated or hairy areas, and have not been treated before.
- At least 6 of those bumps can be surgically removed (you must be willing to have some removed before and after treatment).
- You are in good overall health (able to perform daily activities) and your blood tests show adequate organ function.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control during the study and for 3 months after.
- You have not had certain treatments recently, like chemotherapy, radiation, or other experimental drugs, and you do not have active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This trial tests whether freezing treatment done through the skin (cryotherapy) can reduce pain and discomfort from certain non-cancer NF1 tumors that can’t be safely removed. You may be able to join if you’re an adult with NF1, a painful or bothersome benign lesion, and can safely undergo procedures like MRI.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Hear when a new NF1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.